Cerebrospinal Fluid Biomarkers for Brain Tumors
ConditionCentral Nervous System Neoplasm
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorMayo Clinic
About this trial
This study examines cerebrospinal biomarkers in patients with brain tumors. A biomarker is a measurable indicator of the severity or presence of your disease state. Collecting and storing samples of cerebrospinal fluid from patients with brain tumors to study in the laboratory may help doctors develop new strategies to better diagnose, monitor, and treat brain tumors.
Eligibility criteria
Qualifiers
Any evidence of neoplasm involving the central nervous system (CNS) or its adjacent structures in contact with CSF. Such lesions may include but are not limited to intra-axial or extra-axial lesions, which could be benign, malignant or as yet undefined, involving the brain, spine, meninges, nerves, or vasculature or supporting structures
Subjects must be 18 years of age or older
Disqualifiers
Patients who are under 18 years of age or are a member of a vulnerable population will be excluded from this study
Pregnant women or women who may be pregnant are specifically excluded from study participation
Exception will be granted for patients with diminished capacity to consent if a legally authorized representative is available
Patients without clinical or radiographic evidence of a potentially neoplastic CNS lesion will be excluded
Trial design
Treatments tested in this trial
- Biospecimen Collection
- Electronic Health Record Review
Treatment groups
400 Participants
are divided into 1 treatment groupSponsors and collaborators
Mayo Clinic
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
Collaborator
Source ClinicalTrials.gov